newsfilter
← Latest News
PR Newswire·

Tetra Bio-Pharma Receives EMA Orphan Drug Designation for a Novel Topical Therapeutic Containing CBD

Novel proprietary cannabidiol (CBD) therapeutic has been classified as an orphan medicinal product for the indication of epidermolysis bullosa (EB). Drug is ready for human clinical trials. OTTAWA, ON, May 18, 2022 /PRNewswire/ - Tetra Bio-Pharma Inc